参考文献
［1］Bray F，Jemal A，Grey N，et al.Global cancer transitions according to the Human Development Index（2008-2030）：a population-based study.The Lancet Oncology，2012，13（8）：790-801.
［2］石远凯，孙燕.临床肿瘤内科手册.第6版.北京：人民卫生出版社，2015.
［3］Perez-Lopez R，Lorente D，Blackledge MD，et al.Volume of bone metastasis assessed with whole-body diffusion-weighted imaging is associated with overall survival in metastatic castration-resistant prostate cancer.Radiology，2016，280（1）：151-160.
［4］Stopeck AT，Lipton A，Body JJ，et al.Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer：a randomized，double-blind study.J Clinical Oncology，2010，28（35）：5132-5139.
［5］Fizazi K，Carducci M，Smith M，et al.Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer：a randomized，double-blind study.Lancet（London，England），2011，377（9768）：813-822.
［6］Krzeszinski JY，Wan Y.New therapeutic targets for cancer bone metastasis.Trends in Pharmacological Sciences，2015，36（6）：360-373.
［7］Weilbaecher KN，Guise TA，McCauley LK.Cancer to bone：a fatal attraction.Nature reviews Cancer，2011，11（6）：411-425.
［8］Araujo JC，Trudel GC，Saad F，et al.Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer（READY）：a randomised，double-blind phase 3 trial.The Lancet Oncology，2013，14（13）：1307-1316.
［9］Mitri Z，Nanda R，Blackwell K，et al.TBCRC-010：phaseⅠ/Ⅱ study of dasatinib in combination with zoledronic acid for the treatment of breast cancer bone metastasis.Clinical Cancer Research，2016，22（23）：5706-5712.
［10］Mukherjee K，Chattopadhyay N.Pharmacological inhibition of cathepsin K：A promising novel approach for postmenopausal osteoporosis therapy.Biochemical Pharmacology，2016，117（1）：10-19.
［11］DienstmannR，Rodon J，Serra V，et al.Picking the point of inhibition：a comparative review of P13K/AKT/mTOR pathway inhibitors.Molecular Cancer Therapeutics，2014，13（5）：1021-1031.
［12］Amato RJ，Flaherty A，Zhang Y，et al.Clinical prognostic factors associated with outcome in patients with renal cell cancer with prior tyrosine kinase inhibitors or immunotherapy treated with everolimus.Urologic Oncology，2014，32（3）：345-354.
［13］Ng VC，Johnson JJ，Cuellar S.Targeting the mammalian target of rapamycin pathway with everolimus：implications for the management of metastatic breast cancer.J Oncology Pharmacy Practice，2015，21（6）：433-442.
［14］Broom RJ，Hinder V，Sharples K，et al.Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases：a randomized first-line phase Ⅱ trial.Clinical Genitourinary Cancer，2015，13（1）：50-58.
［15］Davenport AP，Hyndman KA，Dhaun N，et al.Endothelin.Pharmacological Reviews，2016，68（2）：357-418.
［16］Olender J，Nowakowska-Zajdel E，Walkiewicz K，etal.Endothelins and carcinogenesis.PostepyHigieny I MedycynyDoswiadczalnej，2016，70：872-880.
［17］Teoh JP，Park KM，Wang Y，et al.Endothelin-1/endothelin A Receptor-mediated biased signaling is a new player in modulating human ovarian cancer cell tumorigenesis.Cellular Signalling，2014，26（12）：2885-2895.
［18］Restucci B，Martano M，Maiolino P.Expression of endothelin-1 and endothelin-1 receptor A in canine mammary tumours.Research in Veterinary Science，2015，100：182-188.
［19］Carducci MA，Manola J，Nair SG，et al.Atrasentan in patients with advanced renal cell carcinoma：A Phase 2 trial of the ECOG-AC-RIN Cancer research group（E6800）.Clinical Genitourinary Cancer，2015，13（6）：531-539.
［20］Quinn DI，Tangen CM，Hussain M，et al.Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer（SWOG S0421）：a randomised phase 3 trial.The Lancet Oncology，2013，14（9）：893-900.
［21］Nelson JB，Fizazi K，Miller K，et al.Phase 3，randomized，placebo-controlled study of zibotentan（ZD4054）in patients with castration-resistant prostate cancer metastatic to bone.Cancer，2012，118（22）：5709-5718.
［22］Nayak L，Bhattacharyya NP，De RK.Wnt signal transduction pathways：modules，development and evolution.BMC Systems Biology，2016，10（Suppl 2）：44.
［23］Kobayashi Y，Uehara S，Udagawa N，Takahashi N.Regulation of bone metabolism by Wnt signals.J Biochemistry，2016，159（4）：387-392.
［24］Baron R，Kneissel M.WNT signaling in bone homeostasis and disease：from human mutations to treatments.Nature Medicine，2013，19（2）：179-192.
［25］McClung MR，Grauer A，Boonen S，et al.Romosozumab in postmenopausal women with low bone mineral density.The New England J Medicine，2014，370（5）：412-420.(https://www.daowen.com)
［26］Suvannasankha A，Chirgwin JM.Role of bone anabolic agents in the treatment of breast cancer bone metastases.Breast Cancer Research：BCR，2014，16（6）：484.
［27］Fournier PG，Juarez P，Jiang G，et al.The TGF-beta Signaling regulator PMEPA1 Suppresses prostate cancer metastases to bone.Cancer Cell，2015，27（6）：809-821.
［28］Torre La，Bray F，Siegel RL，et al.Global cancer statistics，2012.CA Cancer J Clin，2015，65（2）：87-108.
［29］Ferlay J，Soerjomataram I，Dikshit R，et al.Cancer incidence and mortality worldwide：sources，methods and major patterns in GLOBOCAN 2012.Int J Cancer，2015，136（5）：e359-386.
［30］Hashim D，Boffetta P，LA Vecchia C，et al.The global decrease in cancer mortality：trends and disparities.Ann Oncol，2016，27（5）：926-933.
［31］Akram M，Iqbal M，Daniyal M，et al.Awareness and current knowledge of breast cancer.Biol Res，2017，50（1）：33.
［32］Selli C，Dixon JM，Sims AH.Accurate prediction of response to endocrine therapy in breast cancer patients：current and future biomarkers.Breast Cancer Res，2016，18（118）：1-10.
［33］Dileo A，Jerusalem G，Petruzelka L，et al.Results of the CONFIRM phase Ⅲ trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor positive advanced breast cancer.J Clin Oncol，2010，28（30）：4594-4600.
［34］Ellis MJ，Llombart-Cussac A，Feltl D，et al.Fulvestrant 500 mg versus anastrozole 1 mg for the First？Line treatment of advanced breast cancer：overall survival analysis from the phase Ⅱ FIRST study.J Clin Oncol，2015，33（32）：3781-3787.
［35］Robertson JFR，Llombartcussac A，Rolski J，et al.Activity of fulvestrant 500 mg versus anastrozole 1 mg as first？line treatment for advanced breast cancer：results from the first study.J Clin Oncol，2009，27（27）：4530-4535.
［36］Nathan MR，Schmid P.A review of fulvestrant in breast.Oncol Therapy，2017，5（1）：17.
［37］Infante JR，Gassier PA.Gerecitano JF，et al.A phase I study of the cyclin-dependent kinase 4/6 inhibitor ribociclib（LEE011）in patients with advanced solid tumors and lymphomas.Clin Cancer Res Offic J，2016，22（23）：5696.
［38］Walker AJ Wedam S，Amiri-kordestani L，et al.FDA approval of palbociclib in combination with fulvestrant for the treatment of hormone receptor-rositive，HER2-Negative metastatic breast cancer.Clin Cancer Res，2016，22（20）：4968-4972.
［39］Dorota KZ.Cyclin-dependent kinase 4/6 inhibitors in breast cancer：palbociclib，ribociclib，and abemaciclib.Breast Cancer Res Treat，2017，166：41-54.
［40］Hanamura T，Hayashi SI.Overcoming aromatase inhibitor resistance in breast cancer：possible mechanisms and clinical applications.Breast Cancer，2018，25（4）：1-13.
［41］Abderrahman B，Jordan VC.Improving long-term adjuvant antioestrogenic therapy for breast cancer.New Commun，2017，13：43-47.
［42］ShibataT，Watari K，Izumi H，et al.Breast cancer resistance to antiestrogens is enhanced by increased ER degradation and ERBB2 expression.Cancer Res，2017，77（2）：545-556.
［43］Awolaran OT.Cellular mechanisms of estrogen in breast cancer development.J Sci Technol，2015，3：1-7.
［44］Al-Salama ZT.Apalutamide：first global approval.Drugs，2018，78（6）：699-705.
［45］Smith MR，Saad F，Chowdhury S，et al.Apalutamide treatment and metastasis-free survival in prostate cancer.N Engl J Med，2018，378（15）：1408-1418.
［46］Bubley GJ，Balk SP.Association between androgen receptor splice variants and prostate cancer resistance to abiraterone and enzalutamide.J Clin Oncol，2017，35（19）：2103-2105.
［47］Scher HI，Fizazi K，Saad F，et al.Increased survival with enzalutamide in prostate cancer after chemotherapy.N Engl J Med，2012，367（13）：1187-1197.
［48］Haider MT，Smit DJ，Taipaleenmki H.The endosteal niche in breast cancer bone metastasis.Frontiers in Oncology，2020，10（335）.
［49］Huang R，Wang SQ，Wang N，et al.CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating β-catenin/STAT3 signaling.Cell Death Dis，2020，11（4）：234.
［50］Fizazi K，Scher H，Molina A，et al.Abiraterone Acetate for Treatment of Metastatic Castration-Resistant Prostate Cancer：Final Overall Survival Analysis of the COU-AA-301 Randomised，Double-Blind，Placebo-Controlled Phase 3 Study.Lancet Oncol，2012，13（10）：983-992.